ai in drug development
30 articles about ai in drug development in AI news
FDA to Use AI for Real-Time Drug Trial Monitoring
Bloomberg reports the FDA will deploy AI to monitor clinical trial data in real time, potentially reducing drug testing duration by months by catching issues early.
Eli Lilly Signs $2.75B AI Drug Discovery Deal with Insilico Medicine
Eli Lilly has entered a $2.75 billion licensing pact with Insilico Medicine for multiple AI-discovered drug programs. The deal includes an upfront payment, milestones, and royalties, marking a major validation for AI-driven pharmaceutical R&D.
Beyond General AI: How Liquid Foundation Models Are Revolutionizing Drug Discovery
Researchers have developed MMAI Gym, a specialized training platform that teaches AI the 'language of molecules' to create more efficient drug discovery models. The resulting Liquid Foundation Models outperform larger general-purpose AI while requiring fewer computational resources.
OpenAI Launches GPT-Rosalind for Drug Discovery, GPT-5.4-Cyber for Security
OpenAI launched GPT-Rosalind, a life sciences model performing above the 95th percentile of human experts on novel biological data, and GPT-5.4-Cyber, a cybersecurity variant. These releases, alongside a major Agents SDK update, signal a pivot from general AI to specialized, high-stakes enterprise domains.
XtalPi's Profit Milestone Signals AI's Transformative Impact on Pharmaceutical Discovery
Chinese AI drug discovery firm XtalPi projects its first annual profit in 2025 following a 193% revenue surge, marking a pivotal moment for AI-driven pharmaceutical research. The company's turnaround demonstrates the commercial viability of AI in accelerating drug development pipelines.
Sam Altman Outlines 3 AI Futures: Research, Operations, Personal Agents
OpenAI CEO Sam Altman outlined three potential outcomes for AI development: systems that conduct scientific research, accelerate company operations, and serve as trusted personal agents. This vision frames the strategic direction for OpenAI and the broader industry.
The AI-Powered 'Cocktail': How One Injection Could Revolutionize Healthcare by 2029
A leading AI researcher predicts that within five years, personalized medical treatments delivered via single injections or pills will become reality. This breakthrough promises to democratize access to advanced healthcare through AI-driven drug discovery and delivery systems.
The Great GPU Scramble: How Hardware Shortages Are Defining the AI Arms Race
Oracle founder Larry Ellison identifies GPU acquisition as the primary bottleneck in AI development, with companies racing to secure limited hardware for breakthroughs in medicine, video generation, and autonomous systems.
RxnNano: How a Tiny AI Model Outperforms Giants in Chemical Discovery
Researchers have developed RxnNano, a compact 0.5B-parameter AI model that outperforms models ten times larger in predicting chemical reactions. Using innovative training techniques that prioritize chemical understanding over brute-force scaling, it achieves 23.5% better accuracy on key benchmarks for drug discovery applications.
AI Research Automation Could Arrive by 2027, Raising Security Concerns
New analysis suggests AI systems could fully automate top research teams as early as 2027, potentially accelerating progress in sensitive security domains. This development raises questions about international stability and AI governance.
Cerebras' Strategic Partnership Yields Breakthrough AI Training Results
Cerebras Systems' partnership with Abu Dhabi's G42 has produced remarkable AI training benchmarks, achieving results 100x faster than traditional GPU clusters. The collaboration demonstrates the viability of wafer-scale computing for large language model development.
ML Researcher Uses AlphaFold to Design Treatment for Dog's Cancer in Viral Story
A machine learning researcher reportedly used AlphaFold, DeepMind's protein structure prediction AI, to design a potential treatment for his dog's cancer. The story has gained widespread attention online, highlighting real-world applications of AI in biology.
Anthropic Appoints Novartis CEO Vas Narasimhan to Board via Benefit Trust
Anthropic's independent governance body appointed Vas Narasimhan, CEO of pharmaceutical giant Novartis, to its board. This move connects frontier AI development directly with global healthcare leadership.
DrugPlayGround Benchmark Tests LLMs on Drug Discovery Tasks
A new framework called DrugPlayGround provides the first standardized benchmark for evaluating large language models on key drug discovery tasks, including predicting drug-protein interactions and chemical properties. This addresses a critical gap in objectively assessing LLMs' potential to accelerate pharmaceutical research.
DeepMind's AlphaGenome AI Decodes Non-Coding DNA for CRISPR Targeting
Demis Hassabis states that while CRISPR can edit DNA, finding the right target is hard. DeepMind's AlphaGenome AI is analyzing the non-coding genome to predict mutation effects and guide precise CRISPR interventions.
Legion Health AI Approved for Psychiatric Prescription Renewals in California
San Francisco startup Legion Health received regulatory approval for its AI system to autonomously renew a narrow set of psychiatric prescriptions for stable patients. This represents a carefully guardrailed but significant step toward AI-assisted clinical workflow.
Citadel CEO Ken Griffin Calls AI 'Only Hype' Amid Industry Spend
Citadel CEO Ken Griffin stated AI is 'only hype' and questioned the ROI of massive spending, despite AI's growing integration across industries. This highlights a divide between financial skepticism and technological adoption.
AI Model Analyzes Blood Proteins to Diagnose Alzheimer's, Parkinson's, ALS, and Stroke with 17,187-Patient Study
An AI model can diagnose Alzheimer's, Parkinson's, ALS, frontotemporal dementia, and stroke from a single blood sample by analyzing protein profiles. It outperformed symptom-based diagnosis at predicting future cognitive decline in a Nature-published study of 17,187 people.
Mirendil: Ex-Anthropic Scientists Launch $1B Venture to Build AI That Thinks Like a Scientist
Former Anthropic researchers are raising $175M at a $1B valuation for Mirendil, a startup aiming to build AI systems for long-term scientific reasoning. The goal is to accelerate breakthroughs in biology and materials science, aligning with a broader industry push toward autonomous AI researchers.
The Coming Compute Surge: How U.S. Labs Are Fueling the Next AI Revolution
Morgan Stanley predicts a major AI breakthrough driven by unprecedented computing power increases at U.S. national laboratories. This infrastructure expansion could accelerate AI capabilities beyond current limitations.
AI Research Accelerator: Autonomous System Completes 700 Experiments in 48 Hours, Optimizing Model Training
An AI system autonomously conducted 700 experiments over two days, reducing GPT-2 training time by 11%. This breakthrough demonstrates AI's growing capability to accelerate scientific research and optimize complex processes without human intervention.
ABB and NVIDIA Forge Industrial AI Alliance, Promising 40% Cost Reduction in Robotic Deployment
ABB Robotics and NVIDIA have announced a landmark partnership integrating NVIDIA Omniverse libraries into ABB's RobotStudio platform. The collaboration aims to bridge the sim-to-real gap in industrial robotics, promising deployment cost reductions of up to 40% and 50% faster time-to-market through physically accurate AI simulation.
From Code to Discovery: The Next Frontier of AI Agents in Research
AI researcher Omar Saray predicts a shift from 'agentic coding' to 'agentic research'—where AI systems will autonomously conduct scientific discovery. This evolution promises to accelerate innovation across disciplines.
DishBrain Breakthrough: Lab-Grown Neurons Master Classic Video Game Doom
Scientists have successfully trained in vitro brain cells to play the classic video game Doom, marking a significant advancement in biological computing and neural interface technology. This breakthrough demonstrates how living neurons can process information and adapt to perform complex tasks.
OrbEvo: How AI is Revolutionizing Quantum Chemistry Simulations
Researchers have developed OrbEvo, an equivariant graph transformer that predicts quantum wavefunction evolution in molecules, potentially accelerating time-dependent density functional theory simulations by orders of magnitude. The system accurately captures excited state dynamics and optical properties while maintaining physical symmetries.
MIT's 'Agent Harness' Unleashes Proactive AI That Can Independently Navigate Complex Tasks
MIT researchers have developed a groundbreaking 'agent harness' system that enables AI agents to proactively plan and execute multi-step tasks with minimal human intervention. This represents a significant leap toward truly autonomous AI systems that can navigate complex, real-world scenarios independently.
Lilly's AI Factory: How a 9,000+ GPU SuperPOD is Rewriting Pharmaceutical Discovery
Eli Lilly has launched 'LillyPod,' the world's most powerful privately-owned AI factory for drug discovery. Powered by NVIDIA's new DGX B300 systems with over 1,000 Blackwell Ultra GPUs, it promises to accelerate medical breakthroughs at unprecedented scale.
DeepMind's Diffusion Breakthrough: Training Better Latents for Superior AI Generation
Google DeepMind researchers have developed new techniques for training latent representations in diffusion models, potentially leading to more efficient, higher-quality AI-generated content across images, audio, and video domains.
SymTorch Bridges the Gap Between Black Box AI and Human Understanding
Researchers introduce SymTorch, a framework that automatically converts neural network components into interpretable mathematical equations. This symbolic distillation approach could make AI systems more transparent while potentially accelerating inference, with early tests showing 8.3% throughput improvements in language models.
Google DeepMind Reveals Fundamental Flaw in Diffusion Model Training
Google DeepMind researchers have identified a critical weakness in how diffusion models are trained, challenging the standard approach of borrowing KL penalties from VAEs. Their new paper reveals this method lacks principled control over latent information, potentially limiting model performance.